MHRA promises closer FDA cooperation on AI medical devices at AdvaMed; Japan's PMDA shares principles

Oct 19, 2026 · Issue 12 · 4 sources, 4 articles

At AdvaMed 2026, the MHRA presented the next phase of medtech and AI regulation, which includes closer cooperation with the FDA and more flexible rules. Japan's PMDA published principles for evaluating generative AI-enabled medical devices.

Who is affected and how

medtech company

Closer FDA–MHRA cooperation and the PMDA principles may help companies plan multi-market clearance for AI devices.

health policy

Regulatory convergence makes it possible to align approval practices.

Sources

• Asia-Pacific Roundup: Japan’s PMDA shares principles for evaluating generative AI-enabled medical devicesraps · Oct 19, 2026
• MHRA targets closer FDA ties to accelerate medtech innovationhtworld.co.uk · Oct 19, 2026
• MHRA seeks closer ties with US FDA on MedTech and AI regulationpharmacy business · Oct 20, 2026
• UK regulator brings new AI and MedTech agenda to AdvaMedgov.uk · Oct 19, 2026

Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.